NCT03834272 2026-01-16
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Lumicell, Inc.
Phase 1/2 Completed
Clinical Trials
14 trialsNCT01226550 2025-12-19
Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan
Hospices Civils de Lyon
Phase 1/2 Completed
NCT07273396 2025-12-09
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
Seoul National University Hospital
Phase 1/2 Not yet recruiting
NCT02571725 2025-05-23
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1/2 Active not recruiting
NCT01443260 2025-04-30
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
Genelux Corporation
Phase 1/2 Completed
NCT03618758 2023-12-05
IPLUS
Seoul National University Bundang Hospital
Phase 1/2 Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT00317772 2022-02-07
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02604784 2020-09-17
PI-CaP
Fondazione del Piemonte per l'Oncologia
Phase 1/2 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT03699332 2019-09-13
MMIPC
Radboud University Medical Center
Phase 1/2 Unknown
NCT02219893 2017-05-30
ImmunoPeCa
Oslo University Hospital
Phase 1/2 Completed
NCT01834469 2014-10-15
OV-AP-ICG-IV
Jules Bordet Institute
Phase 1/2 Completed
NCT00103545 2006-10-02
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
AGO Study Group
Phase 1/2 Completed